

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

RETIREMENT OF NON-EXECUTIVE DIRECTOR AND WITHDRAWAL OF ORDINARY RESOLUTION NO.2(C) AT THE 2024 ANNUAL GENERAL MEETING

Reference is made to the circular (the “**2024 AGM Circular**”) of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”) dated April 30, 2024 in relation to the annual general meeting of the Company to be held on Friday, June 28, 2024 at 3:00 p.m. (the “**2024 Annual General Meeting**”), the notice of the 2024 Annual General Meeting dated April 30, 2024 (the “**2024 AGM Notice**”) and the accompanying form of proxy of the Company (the “**2024 AGM Proxy Form**”). Capitalized term used in this announcement shall have the same meanings as those defined in the 2024 AGM Circular unless otherwise defined.

RETIREMENT OF NON-EXECUTIVE DIRECTOR

On June 26, 2024, the Board received a notice of retirement from Ms. Wang Haixia (“**Ms. Wang**”), a non-executive Director, that she shall retire from office at the forthcoming 2024 Annual General Meeting as disclosed in the 2024 AGM Circular and she will not offer herself for re-election at the 2024 Annual General Meeting due to her personal work arrangement (the “**Retirement**”).

Ms. Wang has confirmed that she has no disagreement with the Board, nor is there any matter relating to the Retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its gratitude to Ms. Wang for her contribution and service to the Company during her tenure of office.

WITHDRAWAL OF ORDINARY RESOLUTION NO.2(C) AT THE 2024 ANNUAL GENERAL MEETING

Due to the Retirement, ordinary resolution no.2(c) in respect of the re-election of Ms. Wang as a non-executive Director as set out in the 2024 AGM Notice and the 2024 AGM Proxy Form is no longer applicable and will not be put forward for consideration by the Shareholders at the 2024 Annual General Meeting.

Save as disclosed above, all other resolutions set out in the 2024 AGM Notice and the 2024 AGM Proxy Form shall continue to be valid and be considered at the 2024 Annual General Meeting, and the date, time and venue for holding the 2024 Annual General Meeting shall remain unchanged. The 2024 AGM Proxy Forms lodged by the Shareholders shall remain valid except that no poll will be taken and counted for ordinary resolution no.2(c).

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
Executive Director, Chief Executive Officer and President

Hong Kong, June 26, 2024

As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*